Key result
Phosphodiesterase enzyme type 5 inhibitors (PDE5Is) are proposed as a potential therapeutic option to overcome the inflammatory storm associated with COVID-19 pulmonary disease.
Why the study?
Does the use of phosphodiesterase enzyme type 5 inhibitors (PDE5Is) prevent or improve the inflammatory storm in patients with COVID-19?
Does the use of phosphodiesterase enzyme type 5 inhibitors (PDE5Is) prevent or improve the inflammatory storm in patients with COVID-19?
The authors hypothesize that phosphodiesterase enzyme type 5 inhibitors (PDE5Is) could be repurposed to treat the inflammatory storm in COVID-19 due to their anti-inflammatory properties and presence in lung tissues.
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
No takes yet. Share an insight, caveat, or question.
Al‐kuraishy et al. (2020) conducted a review in COVID-19. Phosphodiesterase enzyme type 5 inhibitors (PDE5Is) was evaluated. Phosphodiesterase enzyme type 5 inhibitors (PDE5Is) are proposed as a potential therapeutic option to overcome the inflammatory storm associated with COVID-19 pulmonary disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: